Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

13 août 2015 08h00 HE | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases

NORCROSS, Ga., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces...
10 août 2015 08h00 HE | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 Financial Results

NORCROSS, Ga., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
15 juil. 2015 16h05 HE | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development

NORCROSS, Ga., July 15, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
29 juin 2015 07h45 HE | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis

NORCROSS, Ga., June 29, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
03 juin 2015 08h00 HE | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Names Dr. Marc Rubin Lead Independent Director

NORCROSS, Ga., June 3, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that...
28 mai 2015 07h30 HE | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at LD Micro Invitational Conference

NORCROSS, Ga., May 28, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today...
15 mai 2015 08h00 HE | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Webcast Corporate Update Following Annual Meeting of Stockholders

NORCROSS, Ga., May 15, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT) will webcast a corporate update at 9:45 A.M. ET on Thursday, May 21, 2015, immediately following the business...
14 mai 2015 08h00 HE | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam

NORCROSS, Ga., May 14, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that...
11 mai 2015 08h00 HE | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase 2 NASH Program

NORCROSS, Ga., May 11, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
24 mars 2015 08h00 HE | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of Liver Diseases Industry Colloquium

NORCROSS, Ga., March 24, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that...

Page précédente